PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ELEV vs. IDYA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ELEV and IDYA is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

ELEV vs. IDYA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Elevation Oncology Inc (ELEV) and IDEAYA Biosciences, Inc. (IDYA). The values are adjusted to include any dividend payments, if applicable.

-50.00%-40.00%-30.00%-20.00%-10.00%0.00%10.00%SeptemberOctoberNovemberDecember2025February
-18.74%
-43.31%
ELEV
IDYA

Key characteristics

Sharpe Ratio

ELEV:

-0.71

IDYA:

-1.14

Sortino Ratio

ELEV:

-0.89

IDYA:

-1.86

Omega Ratio

ELEV:

0.87

IDYA:

0.80

Calmar Ratio

ELEV:

-0.80

IDYA:

-0.95

Martin Ratio

ELEV:

-1.15

IDYA:

-1.79

Ulcer Index

ELEV:

67.88%

IDYA:

30.04%

Daily Std Dev

ELEV:

109.89%

IDYA:

47.13%

Max Drawdown

ELEV:

-97.64%

IDYA:

-74.64%

Current Drawdown

ELEV:

-95.97%

IDYA:

-53.89%

Fundamentals

Market Cap

ELEV:

$38.44M

IDYA:

$1.81B

EPS

ELEV:

-$0.80

IDYA:

-$3.36

Total Revenue (TTM)

ELEV:

$0.00

IDYA:

$7.00M

Gross Profit (TTM)

ELEV:

-$19.00K

IDYA:

-$2.18M

EBITDA (TTM)

ELEV:

-$34.04M

IDYA:

-$182.22M

Returns By Period

In the year-to-date period, ELEV achieves a 15.50% return, which is significantly higher than IDYA's -15.45% return.


ELEV

YTD

15.50%

1M

-8.68%

6M

-18.78%

1Y

-76.54%

5Y*

N/A

10Y*

N/A

IDYA

YTD

-15.45%

1M

-6.13%

6M

-43.31%

1Y

-50.94%

5Y*

25.81%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ELEV vs. IDYA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ELEV
The Risk-Adjusted Performance Rank of ELEV is 1111
Overall Rank
The Sharpe Ratio Rank of ELEV is 1111
Sharpe Ratio Rank
The Sortino Ratio Rank of ELEV is 1212
Sortino Ratio Rank
The Omega Ratio Rank of ELEV is 1111
Omega Ratio Rank
The Calmar Ratio Rank of ELEV is 55
Calmar Ratio Rank
The Martin Ratio Rank of ELEV is 1717
Martin Ratio Rank

IDYA
The Risk-Adjusted Performance Rank of IDYA is 22
Overall Rank
The Sharpe Ratio Rank of IDYA is 22
Sharpe Ratio Rank
The Sortino Ratio Rank of IDYA is 22
Sortino Ratio Rank
The Omega Ratio Rank of IDYA is 55
Omega Ratio Rank
The Calmar Ratio Rank of IDYA is 11
Calmar Ratio Rank
The Martin Ratio Rank of IDYA is 22
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ELEV vs. IDYA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Elevation Oncology Inc (ELEV) and IDEAYA Biosciences, Inc. (IDYA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for ELEV, currently valued at -0.71, compared to the broader market-2.000.002.00-0.71-1.14
The chart of Sortino ratio for ELEV, currently valued at -0.89, compared to the broader market-4.00-2.000.002.004.006.00-0.89-1.86
The chart of Omega ratio for ELEV, currently valued at 0.87, compared to the broader market0.501.001.502.000.870.80
The chart of Calmar ratio for ELEV, currently valued at -0.80, compared to the broader market0.002.004.006.00-0.80-0.95
The chart of Martin ratio for ELEV, currently valued at -1.15, compared to the broader market-10.000.0010.0020.0030.00-1.15-1.79
ELEV
IDYA

The current ELEV Sharpe Ratio is -0.71, which is higher than the IDYA Sharpe Ratio of -1.14. The chart below compares the historical Sharpe Ratios of ELEV and IDYA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00SeptemberOctoberNovemberDecember2025February
-0.71
-1.14
ELEV
IDYA

Dividends

ELEV vs. IDYA - Dividend Comparison

Neither ELEV nor IDYA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ELEV vs. IDYA - Drawdown Comparison

The maximum ELEV drawdown since its inception was -97.64%, which is greater than IDYA's maximum drawdown of -74.64%. Use the drawdown chart below to compare losses from any high point for ELEV and IDYA. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%SeptemberOctoberNovemberDecember2025February
-95.97%
-53.89%
ELEV
IDYA

Volatility

ELEV vs. IDYA - Volatility Comparison

Elevation Oncology Inc (ELEV) has a higher volatility of 19.82% compared to IDEAYA Biosciences, Inc. (IDYA) at 13.54%. This indicates that ELEV's price experiences larger fluctuations and is considered to be riskier than IDYA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%100.00%SeptemberOctoberNovemberDecember2025February
19.82%
13.54%
ELEV
IDYA

Financials

ELEV vs. IDYA - Financials Comparison

This section allows you to compare key financial metrics between Elevation Oncology Inc and IDEAYA Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab